{"url_path":"/sec/plur/8-k/2026-06-01/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1158780/0001213900-26-063500-index.html","accession_number":"0001213900-26-063500","cik":"0001158780","ticker":"PLUR","issuer_name":"Pluri Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1158780/0001213900-26-063500-index.html","primary_entity_key":"0001158780","primary_entity_name":"Pluri Inc."},"word_count":611,"has_tables":true,"body_markdown":"** **\n\n**Item 8.01 Other Events.**\n\n \n\nAs previously disclosed,\nPluri Inc. (the “Company”), together with its subsidiaries, Pluri Biotech Ltd., incorporated under the laws of Israel,\nand Pluristem GmbH, incorporated under the laws of Germany, entered into a finance agreement with the European Investment Bank\n(“EIB”) providing for up to €50 million in funding, of which only the first tranche of €20 million was\ndisbursed in June 2021, and such amount bears interest at 4% per annum, and was scheduled to become repayable on June 1, 2026 (the\n“EIB Loan”). The Company also previously disclosed that on April 21, 2026, the Company received notice from the\nEIB that the EIB was reserving all of its rights under the finance agreement while discussions concerning potential alternatives,\nincluding a possible extension of the maturity date, remained ongoing.\n\n \n\nOn May 28, 2026, the EIB confirmed\nto the Company that the parties remain engaged in constructive discussions in good faith with the objective of exploring a mutually agreed\nresolution regarding the EIB Loan. The EIB further advised that such discussions and negotiations are not expected to extend beyond July\n3, 2026, and that during that period, and without prejudice to any of the EIB’s rights and remedies, no enforcement action is currently\ncontemplated while discussions remain ongoing. The EIB reserved all rights, including the right to take action should the discussions\nnot result in an outcome acceptable to the EIB. No assurance can be given that the parties will reach a mutually acceptable resolution\nor that the EIB will continue to refrain from exercising remedies available to it under the finance agreement.\n\n \n\n**Cautionary Note Regarding\nForward-Looking Statements**\n\n \n\nThis Current Report on Form\n8-K contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995\nand other U.S. federal securities laws. Forward-looking statements include, but are not limited to, statements regarding discussions with\nthe EIB, and the potential resolution of matters relating to the EIB Loan. Words such as “may”, “will”, “should”,\n“could”, “would”, “expect”, “intend”, “plan”, “believe”, “estimate”,\n“target”, “potential”, “continue”, “anticipate”, “seek”, and similar expressions\nare intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.\n\n \n\nForward-looking statements\nare based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ\nmaterially from those expressed or implied by these forward-looking statements. Risks and uncertainties include, among others, the outcome\nand timing of the Company’s discussions with the EIB regarding the EIB Loan, whether those discussions result in a mutually agreed\nresolution, the Company’s liquidity position and need for additional financing, general market and economic conditions, the possibility\nthat the EIB may exercise remedies under the finance agreement and other risks and uncertainties described under the heading “Risk\nFactors” in the Company’s most recent Annual Report on Form 10-K and in other filings the Company makes with the U.S. Securities\nand Exchange Commission (the “SEC”). Forward-looking statements speak only as of the date of this Current Report on Form 8-K.\nThe Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future\nevents, or otherwise, except as required by law. For a more detailed description of the risks and uncertainties affecting the Company,\nreference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission.\n\n \n\n1\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \n**PLURI INC.**\n\n \n \n\nDate: June 1, 2026\nBy:\n/s/ Liat Zalts\n\n \nName: \nLiat Zalts\n\n \nTitle:\nChief Financial Officer\n\n \n\n2"}